abstract |
The present invention relates to the use of amitriptyline as an inhibitor of connexin hemichannels (HC) in the central nervous system (CNS). This HC blocker is advantageously used to treat disorders with misregulated HC, especially neuropathic pain, neurodegenerative disorders, ischemic brain injury and inflammatory bowel conditions. In addition, the present invention provides a method for enhancing the therapeutic effect of amitriptyline on its common efficacy. The method of the invention involves combining amitriptyline with another HC blocker, mefloquine. |